Dyax Corp (DYAX) 38.04 $DYAX
Dyax Shares Up 59.4% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Jun 06, 12:53PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on October 14th, 2015 at $24.10. In approximately 8 months, Dyax has returned 59.38% as of today's recent price of $38.41.
DYAX: 38.04 (-0.37)
Uptrend Call Working As Dyax Stock Rises 59.4% (DYAX)
Comtex SmarTrend(R) - Fri May 27, 12:51PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on October 14th, 2015 at $24.10. In approximately 8 months, Dyax has returned 59.38% as of today's recent price of $38.41.
DYAX: 38.04 (-0.37)
59.4% Return Seen to Date on SmarTrend Dyax Call (DYAX)
Comtex SmarTrend(R) - Fri May 20, 12:22AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on October 14th, 2015 at $24.10. In approximately 7 months, Dyax has returned 59.38% as of today's recent price of $38.41.
DYAX: 38.04 (-0.37)
Dyax Up 59.4% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Thu May 12, 12:51PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on October 14th, 2015 at $24.10. In approximately 7 months, Dyax has returned 59.38% as of today's recent price of $38.41.
DYAX: 38.04 (-0.37)
Dyax Has Returned 59.4% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Mar 21, 1:18PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on October 14th, 2015 at $24.10. In approximately 5 months, Dyax has returned 59.38% as of today's recent price of $38.41.
DYAX: 38.04 (-0.37)
Global Next-Generation Antibody Therapeutics Market - Size, Share, Development, Growth & Demand Forecast to 2020
M2 - Wed Jan 27, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pc7jv/global) has announced the addition of the "Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020" report to their offering. The global next-generation antibody therapeutics market was worth $ 1,328.3 million in 2014, and it is expected to grow at a CAGR of 44% during 2015-2020. Next-generation antibody therapeutics market is escalating with high growth rate due to growing prevalence of chronic diseases. Some of the major reasons leading to increase in number of chronic disease cases include unhealthy lifestyle, poor diet, and addictions, such as smoking, and others. The next-generation antibody therapeutics industry has made huge growth in the recent years. The growing healthcare expenditure has increased the overall research and development investment by various organizations. This leads to the growth of global next-generation antibody therapeutics market. The Autoimmune/Inflammatory market is growing at an average annual growth rate of over 46.4%. The Fc Engineered Antibodies market on the other hand grew at a CAGR of 56.8% during 2015-2020. The restraints associated with next-generation antibody therapeutics market include high cost, stringent regulatory requirements and time consuming approval process of drugs. A significant capital investment is required for the research and manufacturing of next-generation therapeutics. Key Topics Covered: Chapter 1. Research Scope & Methodology Chapter 2. Executive Summary Chapter 3. Market Outlook Chapter 4. Next-Generation Antibody Therapeutics Drug Pipeline Analysis Chapter 5. Global Market Size And Forecast (2014 - 2020) Chapter 6. Next-Generation Antibody Therapeutics Market Breakdown By Therapeutic Area Chapter 7. Next-Generation Antibody Therapeutics Market Breakdown By Technology Chapter 8. Next-Generation Antibody Therapeutics Market Breakdown By Geography Chapter 9. Competitive Positioning And Market Share Analysis Chapter 10. Company Profiles Companies Mentioned: - Amgen Inc. - AstraZeneca PLC. - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen Inc. - Kyowa Hakko Kirin Co. Ltd. - Pfizer Inc. - Seattle Genetics Inc. - Takeda Pharmaceuticals Company Limited - Xencor Inc. For more information visit http://www.researchandmarkets.com/research/2pc7jv/global
SGEN: 40.38 (-0.63), PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), XNCR: 14.48 (-0.18), DYAX: 38.04 (-0.37)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 24.15 (+2.00), BCRX: 3.05 (-0.33), ISIS: 57.56 (-0.28), ARWR: 5.85 (-0.14), SHPG: 177.10 (-6.85), IBIO: 0.61 (-0.02), DYAX: 38.04 (-0.37)
Shire Completes Acquisition of Dyax
PR Newswire Europe - Fri Jan 22, 8:17AM CST
LEXINGTON, Massachusetts, January 22, 2016 /PRNewswire/ --
SHPG: 177.10 (-6.85), DYAX: 38.04 (-0.37)
Technical Scrutiny on Biotechnology Stocks -- Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and Baxalta
ACCESSWIRE - Thu Jan 21, 7:00AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Park Lane Advisor has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Dyax Corporation (NASDAQ: DYAX), and Baxalta Inc. (NYSE: BXLT). Free research report on Gilead Sciences can be accessed at http://www.parklaneadvisor.com/ On Wednesday, January 20, 2016, the NASDAQ Composite ended at 4,471.69, down 0.12%, the Dow Jones Industrial Average declined 1.56%, to finish the day at 15,766.74, and the S&P 500 closed at 1,859.33, down 1.17%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
GILD: 84.45 (-1.32), SRPT: 19.95 (-1.04), BXLT: 46.02 (-0.18), DYAX: 38.04 (-0.37)
Dyax Shares Up 59.4% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Jun 06, 12:53PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on October 14th, 2015 at $24.10. In approximately 8 months, Dyax has returned 59.38% as of today's recent price of $38.41. DYAX: 38.04 (-0.37)
Uptrend Call Working As Dyax Stock Rises 59.4% (DYAX)
Comtex SmarTrend(R) - Fri May 27, 12:51PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on October 14th, 2015 at $24.10. In approximately 8 months, Dyax has returned 59.38% as of today's recent price of $38.41. DYAX: 38.04 (-0.37)
59.4% Return Seen to Date on SmarTrend Dyax Call (DYAX)
Comtex SmarTrend(R) - Fri May 20, 12:22AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on October 14th, 2015 at $24.10. In approximately 7 months, Dyax has returned 59.38% as of today's recent price of $38.41. DYAX: 38.04 (-0.37)
Dyax Up 59.4% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Thu May 12, 12:51PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on October 14th, 2015 at $24.10. In approximately 7 months, Dyax has returned 59.38% as of today's recent price of $38.41. DYAX: 38.04 (-0.37)
Dyax Has Returned 59.4% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Mar 21, 1:18PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on October 14th, 2015 at $24.10. In approximately 5 months, Dyax has returned 59.38% as of today's recent price of $38.41. DYAX: 38.04 (-0.37)
Global Next-Generation Antibody Therapeutics Market - Size, Share, Development, Growth & Demand Forecast to 2020
M2 - Wed Jan 27, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pc7jv/global) has announced the addition of the "Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020" report to their offering. The global next-generation antibody therapeutics market was worth $ 1,328.3 million in 2014, and it is expected to grow at a CAGR of 44% during 2015-2020. Next-generation antibody therapeutics market is escalating with high growth rate due to growing prevalence of chronic diseases. Some of the major reasons leading to increase in number of chronic disease cases include unhealthy lifestyle, poor diet, and addictions, such as smoking, and others. The next-generation antibody therapeutics industry has made huge growth in the recent years. The growing healthcare expenditure has increased the overall research and development investment by various organizations. This leads to the growth of global next-generation antibody therapeutics market. The Autoimmune/Inflammatory market is growing at an average annual growth rate of over 46.4%. The Fc Engineered Antibodies market on the other hand grew at a CAGR of 56.8% during 2015-2020. The restraints associated with next-generation antibody therapeutics market include high cost, stringent regulatory requirements and time consuming approval process of drugs. A significant capital investment is required for the research and manufacturing of next-generation therapeutics. Key Topics Covered: Chapter 1. Research Scope & Methodology Chapter 2. Executive Summary Chapter 3. Market Outlook Chapter 4. Next-Generation Antibody Therapeutics Drug Pipeline Analysis Chapter 5. Global Market Size And Forecast (2014 - 2020) Chapter 6. Next-Generation Antibody Therapeutics Market Breakdown By Therapeutic Area Chapter 7. Next-Generation Antibody Therapeutics Market Breakdown By Technology Chapter 8. Next-Generation Antibody Therapeutics Market Breakdown By Geography Chapter 9. Competitive Positioning And Market Share Analysis Chapter 10. Company Profiles Companies Mentioned: - Amgen Inc. - AstraZeneca PLC. - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen Inc. - Kyowa Hakko Kirin Co. Ltd. - Pfizer Inc. - Seattle Genetics Inc. - Takeda Pharmaceuticals Company Limited - Xencor Inc. For more information visit http://www.researchandmarkets.com/research/2pc7jv/global
SGEN: 40.38 (-0.63), PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), XNCR: 14.48 (-0.18), DYAX: 38.04 (-0.37)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 24.15 (+2.00), BCRX: 3.05 (-0.33), ISIS: 57.56 (-0.28), ARWR: 5.85 (-0.14), SHPG: 177.10 (-6.85), IBIO: 0.61 (-0.02), DYAX: 38.04 (-0.37)
Shire Completes Acquisition of Dyax
PR Newswire Europe - Fri Jan 22, 8:17AM CST
LEXINGTON, Massachusetts, January 22, 2016 /PRNewswire/ --
SHPG: 177.10 (-6.85), DYAX: 38.04 (-0.37)
Technical Scrutiny on Biotechnology Stocks -- Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and Baxalta
ACCESSWIRE - Thu Jan 21, 7:00AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Park Lane Advisor has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Dyax Corporation (NASDAQ: DYAX), and Baxalta Inc. (NYSE: BXLT). Free research report on Gilead Sciences can be accessed at http://www.parklaneadvisor.com/ On Wednesday, January 20, 2016, the NASDAQ Composite ended at 4,471.69, down 0.12%, the Dow Jones Industrial Average declined 1.56%, to finish the day at 15,766.74, and the S&P 500 closed at 1,859.33, down 1.17%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
GILD: 84.45 (-1.32), SRPT: 19.95 (-1.04), BXLT: 46.02 (-0.18), DYAX: 38.04 (-0.37)
